Inspection readiness refers to the state of preparedness a clinical research organization or sponsor maintains to undergo regulatory inspections at any time. It involves having all necessary documentation, processes, and systems in place and readily accessible for review by regulatory authorities such as the FDA or EMA.
This state of readiness requires ongoing maintenance of trial master files, standard operating procedures, and training records. It also encompasses the ability to demonstrate compliance with Good Clinical Practice (GCP) guidelines and applicable regulations throughout the entire clinical trial process.
Inspection readiness is crucial in clinical research as it ensures compliance with regulatory requirements and maintains data integrity. It helps organizations avoid costly delays, fines, or even trial suspension that could result from failed inspections, thus protecting both patient safety and the integrity of clinical study results.
Furthermore, maintaining a state of inspection readiness fosters a culture of quality and continuous improvement within research organizations. It encourages proactive identification and resolution of potential issues, leading to more efficient trial conduct and increased confidence in the reliability of clinical data.
We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…
The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…
Copyright @ 2025 Axcellant